Ultragenyx (RARE) - Total Assets
Based on the latest financial reports, Ultragenyx (RARE) holds total assets worth $1.30 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Ultragenyx (RARE) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Ultragenyx - Total Assets Trend (2011–2025)
This chart illustrates how Ultragenyx's total assets have evolved over time, based on quarterly financial data. Explore RARE strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Ultragenyx - Asset Composition Analysis
Current Asset Composition (December 2025)
Ultragenyx's total assets of $1.30 Billion consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.3% |
| Accounts Receivable | $159.00 Million | 10.4% |
| Inventory | $52.00 Million | 3.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $176.00 Million | 11.5% |
| Goodwill | $44.00 Million | 2.9% |
Asset Composition Trend (2011–2025)
This chart illustrates how Ultragenyx's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ultragenyx (RARE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ultragenyx's current assets represent 62.1% of total assets in 2025, a decrease from 90.3% in 2011.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2025, down from 87.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 11.5% of total assets.
Ultragenyx Competitors by Total Assets
Key competitors of Ultragenyx based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Ultragenyx - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.40 | 7.47 |
| Quick Ratio | 1.85 | 2.24 | 7.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $332.00 Million | $407.49 Million | $822.42 Million |
Ultragenyx - Advanced Valuation Insights
This section examines the relationship between Ultragenyx's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 247.70 |
| Latest Market Cap to Assets Ratio | 1.60 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | $1.53 Billion |
| Market Capitalization | $2.45 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Ultragenyx's assets above their book value (1.60x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Ultragenyx's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ultragenyx (2011–2025)
The table below shows the annual total assets of Ultragenyx from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.53 Billion | +1.90% |
| 2024-12-31 | $1.50 Billion | +0.83% |
| 2023-12-31 | $1.49 Billion | -3.52% |
| 2022-12-31 | $1.55 Billion | +1.51% |
| 2021-12-31 | $1.52 Billion | -13.48% |
| 2020-12-31 | $1.76 Billion | +54.96% |
| 2019-12-31 | $1.14 Billion | +57.80% |
| 2018-12-31 | $719.56 Million | +46.62% |
| 2017-12-31 | $490.75 Million | -9.23% |
| 2016-12-31 | $540.63 Million | -3.39% |
| 2015-12-31 | $559.57 Million | +182.66% |
| 2014-12-31 | $197.97 Million | +231.89% |
| 2013-12-31 | $59.65 Million | -32.46% |
| 2012-12-31 | $88.32 Million | +628.14% |
| 2011-12-31 | $12.13 Million | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more